15 August 2019
Visiongain has launched a new pharma report Pharma Leader Series: Top 30 Ophthalmic Drug Manufacturers 2019-2029: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs.
A specialist sector within the overall pharmaceutical industry, the ophthalmic drugs market is dominated by a relatively small number of companies. The market is relatively mature though with opportunities for growth in key therapeutic areas. Key patent expirations have affected revenues in this market in recent years, particularly in the glaucoma segment.
The lead analyst of the report commented "Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions. Products based on superior technology, particularly those technologies that increase clinical effectiveness or increase patient compliance, are more likely to succeed."
Leading companies featured in the report include Akorn, Allergan, Bayer, Novartis, Pfizer, Regeneron, Roche, Santen Pharmaceuticals, Senju, Valeant and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
11 October 2021
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
07 October 2021
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
06 October 2021
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market